Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis
Latest Information Update: 16 Aug 2025
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 16 Jul 2025 Planned End Date changed from 30 Jun 2025 to 30 Jun 2027.
- 16 Jul 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Jun 2027.
- 17 Jul 2023 This trial has been completed in Lithuania, according to a European Clinical Trials Database record.